Factors Predictive of Remission of Chronic Anterior Uveitis.
Administration, Ophthalmic
Administration, Oral
Adult
Chronic Disease
Female
Follow-Up Studies
Glucocorticoids
/ therapeutic use
Humans
Immunosuppressive Agents
/ therapeutic use
Incidence
Male
Middle Aged
Ophthalmic Solutions
Remission Induction
Retrospective Studies
Risk Factors
Tertiary Care Centers
Uveitis, Anterior
/ diagnosis
Young Adult
Journal
Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
27
01
2019
revised:
16
11
2019
accepted:
21
11
2019
pubmed:
15
1
2020
medline:
15
12
2020
entrez:
15
1
2020
Statut:
ppublish
Résumé
To estimate the incidence of medication-free remission of chronic anterior uveitis and identify predictors thereof. Retrospective cohort study. Patients diagnosed with anterior uveitis of longer than 3 months' duration followed up at United States tertiary uveitis care facilities. Estimation of remission incidence and identification of associated predictors used survival analysis. Incidence of medication-free remission. For the primary analysis, remission was defined as inactive uveitis while off treatment at all visits spanning an interval of at least 90 days or-for patients who did not return for follow-up after 90 days-remaining inactive without receiving suppressive medications at all of the last visits. Association of factors potentially predictive of medication-free remission was also studied. Two thousand seven hundred ninety-five eyes of 1634 patients with chronic anterior uveitis were followed up over 7936 eye-years (4676 person-years). The cumulative medication-free, person-year remission incidence within 5 years was 32.7% (95% confidence interval [CI], 30.4%-35.2%). Baseline clinical factors predictive of reduced remission incidence included longer duration of uveitis at presentation (for 2 to 5 years vs. less than 6 months: adjusted hazard ratio [aHR], 0.61; 95% CI, 0.44-0.83), bilateral uveitis (aHR, 0.75; 95% CI, 0.59-0.96), prior cataract surgery (aHR, 0.70; 95% CI 0.56-0.88), and glaucoma surgery (aHR, 0.63; 95% CI, 0.45-0.90). Two time-updated characteristics were also predictive of reduced remission incidence: keratic precipitates (aHR, 0.36; 95% CI, 0.21-0.60) and synechiae (aHR, 0.62; 95% CI, 0.41-0.93). Systemic diagnosis with juvenile idiopathic arthritis and spondyloarthropathy were also associated with reduced remission incidence. Older age at presentation was associated with higher incidence of remission (for age ≥40 years vs. <40 years: aHR, 1.29; 95% CI, 1.02-1.63). Approximately one third of patients with chronic anterior uveitis remit within 5 years. Longer duration of uveitis, younger age, bilateral uveitis, prior cataract surgery, glaucoma surgery, presence of keratic precipitates and synechiae, and systemic diagnoses of juvenile idiopathic arthritis and spondyloarthropathy predict reduced remission incidence; patients with these factors should be managed taking into account the higher probability of a longer disease course.
Identifiants
pubmed: 31932091
pii: S0161-6420(19)32301-2
doi: 10.1016/j.ophtha.2019.11.020
pmc: PMC7246152
mid: NIHMS1545613
pii:
doi:
Substances chimiques
Glucocorticoids
0
Immunosuppressive Agents
0
Ophthalmic Solutions
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
826-834Subventions
Organisme : NEI NIH HHS
ID : P30 EY001583
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY026717
Pays : United States
Informations de copyright
Copyright © 2019 American Academy of Ophthalmology. All rights reserved.
Références
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
J Ophthalmic Inflamm Infect. 2018 Jun 18;8(1):9
pubmed: 29915970
Am J Ophthalmol. 2011 Feb;151(2):217-22
pubmed: 21145533
Ophthalmology. 2010 Mar;117(3):585-90
pubmed: 20036011
Ophthalmology. 2014 Mar;121(3):778-84
pubmed: 24342020
Semin Ophthalmol. 2018;33(1):64-69
pubmed: 29185838
Best Pract Res Clin Rheumatol. 2016 Oct;30(5):802-825
pubmed: 27964790
Br J Ophthalmol. 2010 Jul;94(7):848-53
pubmed: 20606023
J Rheumatol. 2007 May;34(5):1139-45
pubmed: 17343317
Br J Ophthalmol. 1996 Apr;80(4):332-6
pubmed: 8703885
Ophthalmology. 2015 Jun;122(6):1257-61
pubmed: 25835263
Ophthalmic Epidemiol. 2008 Jan-Feb;15(1):47-55
pubmed: 18300089
Am J Ophthalmol. 2019 Nov;207:170-174
pubmed: 31201796
Annu Rev Public Health. 1993;14:43-68
pubmed: 8323597
Br J Ophthalmol. 2019 Jan;103(1):78-82
pubmed: 29563110
Ocul Immunol Inflamm. 2019;27(7):1105-1113
pubmed: 30142008
Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
pubmed: 15019324
Dev Ophthalmol. 2012;51:1-6
pubmed: 22517200
Ophthalmology. 2011 Oct;118(10):1911-5
pubmed: 21680024
Best Pract Res Clin Rheumatol. 2017 Dec;31(6):846-862
pubmed: 30509444
Am J Ophthalmol. 2007 Apr;143(4):647-55
pubmed: 17224116
Ophthalmology. 2010 Jul;117(7):1436-41
pubmed: 20363502
Ann Rheum Dis. 2005 Jun;64(6):871-4
pubmed: 15897307
JAMA Ophthalmol. 2013 Nov;131(11):1405-12
pubmed: 24008391
Curr Eye Res. 2017 Dec;42(12):1713-1718
pubmed: 28937830
Br J Ophthalmol. 1996 Sep;80(9):844-8
pubmed: 8962842
BMJ. 2009 Jul 03;339:b2480
pubmed: 19578087
Ophthalmologica. 2004 Jul-Aug;218(4):223-36
pubmed: 15258410
J Diabetes Complications. 2018 Jun;32(6):602-608
pubmed: 29656910
Am J Ophthalmol. 2015 Apr;159(4):707-13
pubmed: 25597838